1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Patología Molecular del Cáncer

Patología Molecular del Cáncer

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Fernández-Abad M, Caniego-Casas T, Carretero-Barrio I, Calderay-Domínguez M, Saavedra C, Hardisson D, Palacios J, Pérez-Mies B.

    Ipsilateral Breast Carcinoma Recurrence: True Recurrence or New Primary? A Clinicopathologic and Molecular Study.

    AMERICAN JOURNAL OF SURGICAL PATHOLOGY . 49(3): 294-302.

    [doi:10.1097/PAS.0000000000002351]

  • Tolosa P, Pascual T, Martínez-Saez O, Hernando C, Servitja S, Fernández Abad M, Brasó-Maristany F, Sanfeliu E, Benitez Fuentes JD, Lema L, Ruano Y, García-Fructuoso I, Parrilla L, Rodríguez A, Roncero AM, Cobos MÁ, Sánchez-Bayona R, Alva M, Madariaga A, Villacampa G, Canes J, Salvador F, Sánchez-Belmonte A, Malumbres M, Prat A, Ciruelos E.

    Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study.

    EUROPEAN JOURNAL OF CANCER . 217: 115219-115219.

    [doi:10.1016/j.ejca.2024.115219]

  • Oaknin A, Monk BJ, de Melo AC, Kim HS, Kim YM, Lisyanskaya AS, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin E, Takahashi S, Ramone D, Mackowiak-Matejczyk B, Polastro L, Alia EMG, Colombo N, Makarova Y, Goh JC, Hasegawa K, Mora P, Pikiel J, Srivastav R, Rischin D, Rubio MJ, Perez J, Yoo SY, Gao B, Jamil S, Seebach F, Lowy I, Mathias M, Fury MG, Tewari KS.

    Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial.

    EUROPEAN JOURNAL OF CANCER . 216: 115146-115146.

    [doi:10.1016/j.ejca.2024.115146]

  • González-Martínez S, Palacios J, Carretero-Barrio I, Lanza VF, García-Cosío Piqueras M, Caniego-Casas T, Hardisson D, Esteban-Rodríguez I, Cortés J, Pérez-Mies B.

    Single-Cell RNA Sequencing on Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue Identified Multi-Ciliary Cells in Breast Cancer.

    Cells . 14(3): .

    [doi:10.3390/cells14030197]

  • González-Martín A, Rubio MJ, Heitz F, Depont Christensen R, Colombo N, Van Gorp T, Romeo M, Ray-Coquard I, Gaba L, Leary A, De Sande LM, Lebreton C, Redondo A, Fabbro M, Barretina Ginesta MP, Follana P, Pérez-Fidalgo JA, Rodrigues M, Santaballa A, Sabatier R, Bermejo-Pérez MJ, Lotz JP, Pardo B, Marquina G, Sánchez-Lorenzo L, Quindós M, Estévez-García P, Guerra Alía E, Manso L, Casado V, Kommoss S, Tognon G, Henry S, Bruchim I, Oaknin A, Selle F.

    Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.

    JOURNAL OF CLINICAL ONCOLOGY . 42(36): 4294-4304.

    [doi:10.1200/JCO.24.00668]

  • Ruz-Caracuel I, Pedraza-Arevalo S, Alonso-Gordoa T, Molina-Cerrillo J, Earl J, Sainz B Jr.

    Everything you ever wanted to know about cancer stem cells in neuroendocrine neoplasms but were afraid to ask.

    Endocrine Oncology (bristol, England) . 4(1): .

    [doi:10.1530/EO-24-0006]

  • Grazioso TP, Del Mar Rigual M, Perna C, Caleiras EJ, Djouder N.

    Cold exposure reinstates NAD(+) levels and attenuates hepatocellular carcinoma.

    Cell Stress . 8: 125-139.

    [doi:10.15698/cst2024.12.302]

  • Berges-Gimeno MP, Barra-Castro A, Fernandez-Lozano C, Solano-Solares E, Martinez-Jañez N, Pueyo-Lopez C, Martínez-Botas J.

    Two Nonimmediate Reactions to Oxaliplatin and Docetaxel Confirmed by Lymphocyte Transformation Test and Treated With Successful Rapid Desensitization Procedures.

    Journal of investigational allergology & clinical immunology . : 0-0.

    [doi:10.18176/jiaci.1030]

  • Bonura GF, Biancheri P, Rainer J, Soriani P, Rodriguez de Santiago E, Parrella A, Campioli A, Guerra E, Gualdi E, Pignatti A, Manno M.

    Spinal anesthesia for endoscopic submucosal dissection of large rectosigmoid lesions: Feasibility study.

    Endoscopy International Open . 12(12): 1447-1452.

    [doi:10.1055/a-2441-2543]

  • Montégut C, Falandry C, Cinieri S, Cropet C, Montane L, Rousseau F, Joly F, Moubarak M, Mosconi AM, Guerra-Alía EM, Schauer C, Fujiwara H, Vergote I, Parma G, Lindahl G, Anota A, Canzler U, Marmé F, Pujade-Lauraine E, Ray-Coquard I, Sabatier R.

    Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA-1/ENGOT-ov25.

    ONCOLOGIST . : .

    [doi:10.1093/oncolo/oyae322]

  • Mata-Castro N, Castañeda-Vozmediano R, Perna C, Prada Puentes C, Sanz López L.

    Histological Findings of Resected Tracheal Ring in SARS-CoV-2-Positive and -Negative Tracheostomized Patients.

    LIFE-BASEL . 14(12): .

    [doi:10.3390/life14121655]

  • Kime A, Bataillon G, Treilleux I, Callens C, Selle F, Heitz F, Cinieri S, González-Martin A, Schauer C, Lindahl G, Parma G, Vergote I, Matsumoto T, Blonz C, Canzler U, Mosconi AM, Guerra Alía EM, Pujade-Lauraine E, Genestie C, Ray-Coquard I, Just PA.

    Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma?

    Archives of pathology & laboratory medicine . : .

    [doi:10.5858/arpa.2024-0081-OA]

  • Garcia-Donas, Jesus, Garrigos, Laia, Lainez, Nuria, Santaballa, Ana, Redondo, Andres, Cueva, Juan Fernando, Rubio, M. Jesus, Prieto, Mario, Lopez-Guerrero, Jose Antonio, Garcia-Casado, Zaida, Barquin, Aranzanzu, Grande, Enrique, Alia, Eva Guerra, Sevillano, Elena, Bover, Isabel, Grazioso, Tatiana P., Sanchez-Escribano, Ramon, Hurtado, Alicia, Navarro, Paloma, Rodriguez-Moreno, Juan Francisco.

    Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01)

    CLINICAL & TRANSLATIONAL ONCOLOGY . : .

    [doi:10.1007/s12094-024-03827-4]

  • Cortés A, López-Miranda E, Fernández-Ortega A, Carañana V, Servitja S, Urruticoechea A, Lema-Roso L, Márquez A, Lazaris A, Alcalá-López D, Mina L, Gener P, Rodríguez-Morató J, Antonarelli G, Llombart-Cussac A, Pérez-García J, Cortés J.

    Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study.

    Breast . 78: 103834-103834.

    [doi:10.1016/j.breast.2024.103834]

  • Matias-Guiu X, Lax S, Raspollini MR, Palacios J, Zheng W, Liu C, de Brot L, Lordello L, Hardisson D, Gaffney D, Mutch D, Scambia G, Creutzberg CL, Fotopoulou C, Berek JS, Concin N.

    FIGO 2023 staging for endometrial cancer, when, if it is not now?

    EUROPEAN JOURNAL OF CANCER . 213: 115115-115115.

    [doi:10.1016/j.ejca.2024.115115]

  • Palacios P, Palacios I, Palacios A, Lorente A, Mariscal G, Benlloch M, Palacios J.

    Effect of bariatric surgery on postoperative outcomes of total hip arthroplasty: An updated systematic review and meta-analysis.

    ASIAN JOURNAL OF SURGERY . : .

    [doi:10.1016/j.asjsur.2024.11.003]

  • Cortés-Salgado A, Serrano JJ, Cordero Pereda D, Menacho M, del Rey JM, Del Campo-Albendea L, Saavedra C, Chamorro J, Rosero D, Sotoca P, Guillén-Ponce C, Guerra E, Fernández-Abad M, López-Miranda E, Martínez-Jáñez N, Gion M, Salazar MT, Agudo-Quílez P, Garrido P, Alonso Salinas GL.

    Anthracyclines-induced cardiotoxicity in patients with early breast cancer carrying germline BRCA1/2 mutation: the BRCAN study.

    ONCOLOGIST . : .

    [doi:10.1093/oncolo/oyae299]

  • Quintela-Fandino M, Bermejo B, Zamora E, Moreno F, Garcia-Saenz JÁ, Pernas S, Martinez Jañez N, Jiménez D, Adrover E, Andrés R, Mourón S, Bueno MJ, Manso L, Viñas G, Alba E, Llombart-Cussac A, Cortes J, Tebar C, Roe DJ, Grant A, Watson A, Colomer R, Mouneimne G.

    High mechanical conditioning by tumor extracellular matrix stiffness is a predictive biomarker for anti-fibrotic therapy in HER2-negative breast cancer.

    CLINICAL CANCER RESEARCH . 30(22): 5094-5104.

    [doi:10.1158/1078-0432.CCR-24-1518]